CompletedPhase 2NCT02509598
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cardinal Health 414, LLC
- Principal Investigator
- Michael Blue, MDCardinal Health 414, LLC
- Intervention
- Tc99m tilmanocept(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2015 – 2019
Study locations (6)
- Nemours Children's Specialty Care, Jacksonville, Florida, United States
- Nemours Children's Hopsital, Orlando, Florida, United States
- Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02509598 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC